Please login to the form below

Not currently logged in
Email:
Password:

Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company

Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  

She joined the company in 2009 as VP of business development and, since 2011, had served as senior vice president and chief business officer and sat on Zealand's executive management team.  

David Solomon, Zealand's president and CEO, said: “Arvind Hundal has made valuable contributions to building Zealand's large portfolio of partnership agreements over the past five years.  

“It is to a large extent also thanks to Arvind and the team's achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavours.”  

Before joining Zealand Dr Hundal, who has over 20 years of experience in the life sciences sector, served as a member of AstraZeneca's strategic planning business development organisation and as business development director at Danish biotech 7TM Pharma.

15th December 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...